We are analyzing https://link.springer.com/article/10.1007/s12094-009-0329-7.

Title:
Tumoral angiogenesis and breast cancer | Clinical and Translational Oncology
Description:
Breast cancer (BC) is the most common neoplasm in women in Western countries. Tumoral angiogenesis (TA) is essential for the growth and spread of BC cells. There are at least 6 different angiogenic growth factors associated with TA in BC. The major mediator of TA is vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glycoprotein. VEGF signals through VEGF receptor-2 (VEGFR-2), the major VEGF signalling receptor that mediates sprouting angiogenesis. Recently, different antiangiogenic agents have shown efficacy in the treatment of advanced BC. Bevacizumab, a humanised monoclonal antibody against VEGF, in combination with taxanes improves progression-free survival and overall response rate in first-line therapy. Other new antiangiogenic agents, called multi-kinase inhibitors (sunitinib and pazopanib), are under investigation. Finally, a schedule of treatment called metronomic chemotherapy, with antiangiogenic activity, has also demonstrated efficacy in the treatment of advanced BC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, google, scholar, article, pubmed, cas, breast, angiogenesis, growth, factor, oncol, clin, bevacizumab, metastatic, khosravi, vascular, endothelial, vegf, metronomic, med, content, advanced, therapy, privacy, cookies, antiangiogenic, chemotherapy, access, tumor, patients, publish, search, tumoral, shahi, receptor, treatment, res, nat, phase, trial, paclitaxel, data, information, log, journal, research, clinical, oncology, parham, soria,

Topics {✒️}

month download article/chapter called multi-kinase inhibitors homodimeric heparin-binding glycoprotein csf-1r-dependent osteolysis /ii dose-escalation trial parham khosravi shahi vegf-specific antibody bevacizumab hypoxia-inducible factor metastatic breast cancer full article pdf soria lovelle privacy choices/manage cookies advanced breast cancer hormone receptor-positive key regulatory factor human rectal cancer translational oncology aims related subjects angiogenic growth factors factor inhibiting hif mediates sprouting angiogenesis pérez-manga pérez manga humanised monoclonal antibody bmc cancer 6 her2- positive advanced high tumor levels prolonged clinical benefit su11248 inhibits kit phase ii multicenter european economic area universal chemosensitization strategy cupin structural family murray lj pharmacokinetic/pharmacodynamic relationship article clinical conditions privacy policy phase ii study breast cancer accepting optional cookies tumor growth check access instant access article log tumor angiogenesis vegf receptor-2 bevacizumab versus paclitaxel vivo antitumor activity journal finder publish author correspondence

Questions {❓}

Gasparini G (2001) Metronomic scheduling: the future of chemotherapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tumoral angiogenesis and breast cancer
         description:Breast cancer (BC) is the most common neoplasm in women in Western countries. Tumoral angiogenesis (TA) is essential for the growth and spread of BC cells. There are at least 6 different angiogenic growth factors associated with TA in BC. The major mediator of TA is vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glycoprotein. VEGF signals through VEGF receptor-2 (VEGFR-2), the major VEGF signalling receptor that mediates sprouting angiogenesis. Recently, different antiangiogenic agents have shown efficacy in the treatment of advanced BC. Bevacizumab, a humanised monoclonal antibody against VEGF, in combination with taxanes improves progression-free survival and overall response rate in first-line therapy. Other new antiangiogenic agents, called multi-kinase inhibitors (sunitinib and pazopanib), are under investigation. Finally, a schedule of treatment called metronomic chemotherapy, with antiangiogenic activity, has also demonstrated efficacy in the treatment of advanced BC.
         datePublished:2009-03-27T00:00:00Z
         dateModified:2009-03-27T00:00:00Z
         pageStart:138
         pageEnd:142
         sameAs:https://doi.org/10.1007/S12094-009-0329-7
         keywords:
            VEGF
            Sunitinib
            Bevacizumab
            Metronomic chemotherapy
            Pazopanib
            Oncology
         image:
         isPartOf:
            name:Clinical and Translational Oncology
            issn:
               1699-3055
               1699-048X
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Milan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Parham Khosravi Shahi
               affiliation:
                     name:Hospital General Universitario Gregorio Marañón
                     address:
                        name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Alicia Soria Lovelle
               affiliation:
                     name:Hospital General Universitario Gregorio Marañón
                     address:
                        name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gumersindo Pérez Manga
               affiliation:
                     name:Hospital General Universitario Gregorio Marañón
                     address:
                        name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tumoral angiogenesis and breast cancer
      description:Breast cancer (BC) is the most common neoplasm in women in Western countries. Tumoral angiogenesis (TA) is essential for the growth and spread of BC cells. There are at least 6 different angiogenic growth factors associated with TA in BC. The major mediator of TA is vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glycoprotein. VEGF signals through VEGF receptor-2 (VEGFR-2), the major VEGF signalling receptor that mediates sprouting angiogenesis. Recently, different antiangiogenic agents have shown efficacy in the treatment of advanced BC. Bevacizumab, a humanised monoclonal antibody against VEGF, in combination with taxanes improves progression-free survival and overall response rate in first-line therapy. Other new antiangiogenic agents, called multi-kinase inhibitors (sunitinib and pazopanib), are under investigation. Finally, a schedule of treatment called metronomic chemotherapy, with antiangiogenic activity, has also demonstrated efficacy in the treatment of advanced BC.
      datePublished:2009-03-27T00:00:00Z
      dateModified:2009-03-27T00:00:00Z
      pageStart:138
      pageEnd:142
      sameAs:https://doi.org/10.1007/S12094-009-0329-7
      keywords:
         VEGF
         Sunitinib
         Bevacizumab
         Metronomic chemotherapy
         Pazopanib
         Oncology
      image:
      isPartOf:
         name:Clinical and Translational Oncology
         issn:
            1699-3055
            1699-048X
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Milan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Parham Khosravi Shahi
            affiliation:
                  name:Hospital General Universitario Gregorio Marañón
                  address:
                     name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Alicia Soria Lovelle
            affiliation:
                  name:Hospital General Universitario Gregorio Marañón
                  address:
                     name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gumersindo Pérez Manga
            affiliation:
                  name:Hospital General Universitario Gregorio Marañón
                  address:
                     name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical and Translational Oncology
      issn:
         1699-3055
         1699-048X
      volumeNumber:11
Organization:
      name:Springer Milan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hospital General Universitario Gregorio Marañón
      address:
         name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
         type:PostalAddress
      name:Hospital General Universitario Gregorio Marañón
      address:
         name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
         type:PostalAddress
      name:Hospital General Universitario Gregorio Marañón
      address:
         name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Parham Khosravi Shahi
      affiliation:
            name:Hospital General Universitario Gregorio Marañón
            address:
               name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Alicia Soria Lovelle
      affiliation:
            name:Hospital General Universitario Gregorio Marañón
            address:
               name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Gumersindo Pérez Manga
      affiliation:
            name:Hospital General Universitario Gregorio Marañón
            address:
               name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
      name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
      name:Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(109)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.35s.

LINK . SPRINGER . COM {}